Orion Corporation: Managers’ transactions – Hilpi Rautelin
ORION CORPORATION MANAGERS’ TRANSACTIONS 30 AUGUST 2023 at 15.30 EEST Orion Corporation: Managers’ transactions – Hilpi Rautelin Orion Corporation has...
Pharmaceutical
Clene to Present at Upcoming September Conferences
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad’s lifelong work NEW YORK, NY, ALPHARETTA, GA...
Cognition Therapeutics Announces Participation in Upcoming September Conferences
PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative...
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
BioHarvest Sciences Reports Q2 2023 Results Demonstrating Continued Growth Momentum
Q2 VINIA® revenues of USD 2.75M represent growth of 228% compared to Q2 2022 and 27% compared to Q1 2023...
IRLAB publishes interim report for the period January-June 2023
GOTHENBURG, SE / ACCESSWIRE / August 30, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, August 30, 2023 - IRLAB Therapeutics...
Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin (Zypitamag) to People Living With HIV
WINNIPEG, MB / ACCESSWIRE / August 29, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on...
Theralase Release’s 2Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / August 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Barry Simms Named as Elligo Health Research’s Chief Operating Officer
AUSTIN, Texas--(BUSINESS WIRE)--Elligo Health Research®, the largest healthcare-enabling research organization, today announced the addition of Barry Simms as Elligo’s Chief...
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing...
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in...
Digipath Announces Record Earnings of $292,533 for Recent Quarter Ended June 30
Digipath, Inc. High capacity LCMS-QQQ for testing pesticidesLab Operations has Seen a Consistent Uptick in Sample Flow LAS VEGAS, NV,...
Evaxion announces Executive Management Changes to strengthen the AI-strategy
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulationsPRINCETON,...
Olink to participate in September investor events
UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management...
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion rates of 3,000mg via IV...
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a...
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVEZORYVE is a once-daily, steroid-free...